|Bid||0.00 x 1100|
|Ask||177.56 x 800|
|Day's range||173.20 - 180.85|
|52-week range||79.41 - 180.85|
|Beta (5Y monthly)||1.35|
|PE ratio (TTM)||10.21|
|Earnings date||16 Apr 2021|
|Forward dividend & yield||4.60 (2.65%)|
|Ex-dividend date||15 Jan 2021|
|1y target est||164.68|
Harris Williams, a global investment bank specializing in M&A advisory services, announces it advised Chequers Capital on its acquisition of 7days, a portfolio company of Silverfleet Capital (Silverfleet). 7days is a leading direct-to-consumer supplier of fashionable workwear for medical professionals. The transaction was led by professionals from the Harris Williams Consumer Group, including Andreas Poth and Konstantin Molinari of the firm’s Frankfurt office, Ed Arkus of the firm’s London office and Corey Benjamin of the firm’s Richmond office.
Early Warning Services, LLC and The Clearing House (TCH) today announced Zelle® transactions can now be cleared and settled over the RTP® network.
Harris Williams, a global investment bank specializing in M&A advisory services, announces it is the lead advisor to Altasciences, a portfolio company of Audax Private Equity, on its pending sale to Novo Holdings A/S (Novo Holdings). Founded in 1992, Altasciences is a fully integrated, early drug development services platform, providing the pharma and biotech industries with a trusted partner for drug development, from preclinical safety testing through to clinical proof-of-concept studies. The transaction is being led by Paul Hepper, Geoffrey Smith, Tyler Bradshaw, Miles Annin and Bill Whitaker of the Harris Williams Healthcare & Life Sciences (HCLS) Group and Daniel Wang, a managing director leading the firm’s efforts in Asia.